United States Patent 8,236,816: Scope, Claims, Expiration, and Patent Landscape for 3.75% Imiquimod
U.S. Patent No. 8,236,816 protects a six-week, field-directed treatment regimen using 3.75% imiquimod for actinic keratoses on the full face or balding scalp of immunocompetent adults. The core regimen is two weeks of once-daily treatment, two weeks without treatment, and two further weeks of once-daily treatment. The patent is a method-of-use patent rather than a broad composition patent.
The patent is associated with Zyclara 3.75% cream, marketed for actinic keratoses under FDA-approved NDA 022483. The Orange Book-listed patent term is generally reported to expire on May 12, 2026. The principal commercial risk is a generic or authorized-generic product that copies the same concentration and regimen, although a product using a different concentration, schedule, or labeled indication may avoid literal infringement.
What does U.S. Patent 8,236,816 protect?
The patent protects the use of 3.75% imiquimod in a defined six-week treatment course. Claim 1 contains the controlling limitations:
| Limitation |
Required scope |
| Patient |
Immunocompetent adult |
| Disease |
Actinic keratoses |
| Active ingredient |
Imiquimod as the sole required active pharmaceutical ingredient |
| Concentration |
3.75% weight/weight |
| Route |
Topical application |
| Treatment site |
Full face or balding scalp |
| First treatment period |
Once daily for two weeks |
| Rest period |
Two weeks with no imiquimod application |
| Second treatment period |
Once daily for two weeks |
| Total course |
Six weeks |
The claim is directed to treatment of a broad skin field rather than individual lesion treatment. That distinction matters because the regimen applies to the entire face or balding scalp, including clinically visible, palpable, or subclinical lesions.
The claim set also includes quantitative dosing, administration, treatment-outcome, and anatomical limitations. Claims 2 through 7 define the amount of cream or imiquimod delivered. Claims 8 through 10 and 18 address clearance outcomes. Claims 11 through 17 address lesion characteristics, treatment continuation, surface area, and duration of skin contact.
How should the supplied claims be read?
The supplied text contains apparent transcription errors. The operative terms should be read as “full face” rather than “frill face” or “inn face.” The claim structure is consistent with the FDA-approved Zyclara regimen and the issued patent’s subject matter.
A cleaned interpretation of claim 1 is:
A method of treating actinic keratoses in an immunocompetent adult by applying 3.75% imiquimod once daily to the full face or balding scalp for two weeks, withholding treatment for two weeks, and applying the same composition once daily for a further two weeks, with imiquimod as the sole required active pharmaceutical ingredient.
The phrase “in a six week treatment course” defines the overall treatment duration. The two-week non-treatment interval is not optional. A regimen that uses continuous daily treatment, a shorter rest period, or a different number of treatment cycles would not satisfy every limitation of claim 1.
What are the dependent claim limitations?
| Claim |
Added limitation |
| 2 |
Application of 250 to 500 mg of the composition |
| 3 |
Composition remains on the skin for about eight hours |
| 4 |
Daily imiquimod dose of 9.3 to 18.8 mg |
| 5 |
Weekly imiquimod dose of 65.6 to 131.3 mg during a two-week treatment period |
| 6 |
131.2 to 262.5 mg during a two-week treatment period |
| 7 |
262.5 to 525 mg over the six-week course |
| 8 |
Complete clearance of actinic keratoses |
| 9 |
Statistically significant improvement in total clearance versus placebo |
| 10 |
About 25% or greater complete clearance in the treated population |
| 11 |
Clinically typical, visible, or palpable actinic keratoses |
| 12 |
Temporary increase in the number of visible actinic keratoses |
| 13 |
Treatment continues for the full two-week period even if lesions are no longer visible |
| 14 |
Application to the full face |
| 15 |
Application to the balding scalp |
| 16 |
Full-face treatment area of at least 200 to 250 cm² |
| 17 |
The approximately eight-hour exposure occurs overnight |
| 18 |
Clearance of at least 75% of baseline actinic keratoses |
Dependent claims are narrower than claim 1. They may be useful in litigation if a competing product or label avoids one feature of the broad claim but falls within a specific dosing, exposure, or treatment-outcome limitation.
What is the strongest infringement theory?
The strongest literal-infringement case would involve a product or treatment instruction that states:
- 3.75% imiquimod;
- once-daily application;
- full-face or balding-scalp treatment;
- two treatment weeks;
- two treatment-free weeks;
- two additional treatment weeks; and
- treatment of immunocompetent adults with actinic keratoses.
A generic label that reproduces the Zyclara prescribing instructions would present the clearest inducement-of-infringement risk. The relevant evidence would include the proposed labeling, product concentration, package instructions, dosage packet size, clinical studies, and promotional materials.
The “sole active pharmaceutical ingredient required” limitation narrows the claim in one respect. A product containing imiquimod as the only therapeutic active ingredient would fit the language more directly than a combination product with another pharmacologically active compound. The limitation does not require that the formulation contain no excipients.
What do the dosing claims protect?
The dosing claims are designed to capture the practical amount of Zyclara applied during the regimen. A 3.75% formulation contains approximately 37.5 mg of imiquimod per gram of cream. Applying 250 to 500 mg of cream therefore delivers approximately 9.4 to 18.8 mg of imiquimod, corresponding closely to claim 4.
The quantitative limitations create internal consistency:
| Parameter |
Claimed range |
| Cream per application |
250-500 mg |
| Imiquimod per day |
9.3-18.8 mg |
| Imiquimod per treatment week |
65.6-131.3 mg |
| Imiquimod per two-week treatment period |
131.2-262.5 mg |
| Imiquimod per six-week course |
262.5-525 mg |
A product labeled for a smaller lesion area or lower application amount may avoid claims 2, 4, 5, 6, and 7 while still potentially implicating claim 1 if the full-face or balding-scalp regimen is otherwise instructed.
When does U.S. Patent 8,236,816 lose exclusivity?
| Event |
Date or status |
| Patent |
U.S. 8,236,816 |
| Patent type |
Method of treatment |
| Product associated with the patent |
Zyclara 3.75% cream |
| FDA product |
NDA 022483 |
| Orange Book status |
Listed patent associated with the NDA |
| Reported expiration |
May 12, 2026 |
| Regulatory exclusivity |
Separate from patent protection; must be evaluated under the FDA exclusivity record |
| Post-expiration entry |
Subject to FDA approval, patent certification, and any litigation or settlement constraints |
Patent expiration does not automatically produce generic market entry. A generic applicant must obtain FDA approval and address listed patents through the applicable ANDA certification process. A Paragraph IV certification can trigger litigation and a statutory 30-month stay if the NDA holder or patent owner files suit within the statutory period.
What is the Orange Book status of Zyclara?
Zyclara 3.75% cream was approved by the FDA for the topical treatment of actinic keratoses of the full face or balding scalp in immunocompetent adults. The product uses a six-week regimen consisting of two treatment weeks, two weeks without treatment, and two further treatment weeks.[1]
The Orange Book identifies patents submitted by an NDA sponsor for a listed drug. Listing does not establish that every claim is valid or infringed. It determines the patent certifications that an ANDA applicant must make and can create statutory litigation consequences under the Hatch-Waxman Act.[2]
The principal listed patent associated with the six-week 3.75% regimen is U.S. 8,236,816. Any current Orange Book status should be read together with the FDA’s live patent listing because listings, delistings, and product-specific records can change.
Are there Paragraph IV challenges to U.S. 8,236,816?
A Paragraph IV challenge requires a generic applicant to certify that a listed patent is invalid, unenforceable, or will not be infringed. Publicly available FDA and court records should be reviewed for any ANDA litigation involving a proposed 3.75% imiquimod product.
The commercial significance of a Paragraph IV filing depends on four factors:
- whether the ANDA duplicates the patented six-week regimen;
- whether the generic sponsor seeks a carve-out for the patented method;
- whether the patent owner files suit within 45 days;
- whether the litigation produces a settlement, judgment, or license.
A formulation-only generic that uses 3.75% imiquimod but seeks labeling limited to a non-infringing use could present a different risk profile from a product that copies the full-face or balding-scalp indication and dosing schedule.
How strong is the patent estate for Zyclara?
The estate’s principal strength is regimen specificity. The patent does not merely claim imiquimod for actinic keratoses. It claims a particular concentration, treatment site, treatment population, daily frequency, rest interval, and six-week course.
Its principal weaknesses are the same limitations that create its commercial value:
- Earlier imiquimod use for actinic keratoses was known, particularly with 5% formulations.
- A challenger could argue that the 3.75% regimen was obvious based on earlier clinical data, dose-ranging work, and known imiquimod treatment schedules.
- The numerical dosing claims may face written-description or enablement scrutiny if the specification does not adequately support the full ranges.
- Treatment-outcome claims may depend on the patient population, trial design, endpoint definition, and statistical evidence.
- The “sole active pharmaceutical ingredient required” language may create claim-construction disputes over combination products and formulation ingredients.
The patent is stronger against a direct copy of the approved Zyclara label than against a lower-dose, shorter-course, lesion-directed, or differently labeled product.
How does the patent compare with earlier Aldara protection?
| Issue |
Aldara 5% |
Zyclara 3.75% |
| Active ingredient |
Imiquimod |
Imiquimod |
| Concentration |
5% |
3.75% |
| Typical treatment approach |
Lesion-directed or area-specific regimens |
Field-directed full-face or balding-scalp regimen |
| Course structure |
Varies by indication and labeling |
Two weeks on, two weeks off, two weeks on |
| Key patent issue |
Earlier composition and use patents |
Six-week low-concentration treatment method |
| Generic exposure |
5% imiquimod generics are established |
3.75% regimen-specific entry is more constrained by the method patent |
The existence of generic 5% imiquimod does not by itself authorize use of that product under the patented 3.75% six-week regimen. Concentration, labeling, dosage instructions, and treatment site remain material.
What formulation patents and manufacturing barriers matter?
U.S. 8,236,816 does not broadly claim every 3.75% imiquimod cream formulation. A competing manufacturer could attempt to use a different cream base, packaging configuration, preservative system, or manufacturing process while still raising method-of-use concerns if its label directs the patented regimen.
Relevant technical barriers include:
- maintaining uniform 3.75% imiquimod concentration;
- controlling particle size and suspension stability;
- achieving consistent dose delivery from single-use packets;
- preserving product stability during storage;
- matching skin tolerability and irritation characteristics;
- producing a formulation suitable for full-face application.
A separate formulation or manufacturing patent could provide additional protection, but it would need to be distinguished from the method claims of U.S. 8,236,816. The patent number supplied here does not, by itself, establish a broad formulation monopoly.
What litigation and settlement issues affect generic entry?
Potential litigation would likely focus on claim construction, obviousness, anticipation, written description, enablement, and infringement by the proposed label. The most important factual dispute would be whether the generic product’s FDA labeling encourages the complete six-week regimen on the full face or balding scalp.
A settlement could establish a licensed entry date before patent expiration. The relevant documents would include the complaint, ANDA number if disclosed, proposed labeling, patent certifications, settlement terms, and any Federal Trade Commission review. No settlement date should be assumed from patent expiration alone.
What is the commercial and revenue exposure?
Zyclara revenue is generally not reported as a separately disclosed product line in public financial statements. Revenue exposure must therefore be estimated from prescription volume, net price, payer coverage, market share, and the availability of generic 5% imiquimod.
The commercial risk is concentrated in the branded 3.75% product and its FDA-labeled full-face or balding-scalp use. Generic 5% imiquimod competition does not necessarily replace Zyclara because the products have different concentrations and labeling, but it can constrain pricing and physician adoption.
What generic launch scenarios exist?
| Scenario |
Patent risk |
Commercial timing |
| Generic copies Zyclara label |
High literal infringement risk |
Possible after patent expiration or earlier settlement |
| Generic seeks a label carve-out |
Depends on omitted indication and instructions |
Earlier entry may be possible |
| Generic uses 5% imiquimod |
Does not directly copy 3.75% formulation |
Separate product and labeling analysis |
| New 3.75% formulation with different regimen |
Lower claim overlap if regimen differs |
FDA approval and method claims remain relevant |
| Combination product |
May avoid “sole active” limitation |
Other patents and regulatory requirements apply |
Key Takeaways
- U.S. 8,236,816 is a method-of-use patent covering the six-week 3.75% imiquimod regimen for actinic keratoses.
- Claim 1 requires immunocompetent adults, full-face or balding-scalp application, two weeks on, two weeks off, and two weeks on.
- Claims 2 through 7 add cream-volume and imiquimod-dose ranges.
- Claims 8 through 18 add clearance, lesion, treatment-continuation, exposure-time, and anatomical limitations.
- The patent is associated with Zyclara 3.75% cream and FDA NDA 022483.
- The reported Orange Book expiration date is May 12, 2026.
- A generic copying the approved Zyclara label would face the greatest infringement exposure.
- Generic 5% imiquimod products do not automatically avoid the method claims if their labeling encourages the patented regimen, but concentration and labeling differences are material.
- No separate revenue figure for Zyclara can be derived from ordinary public financial reporting without product-level disclosure.
FAQs
Does U.S. 8,236,816 cover imiquimod itself?
No. The patent primarily covers a treatment method using 3.75% imiquimod in a specified regimen. It is not a basic compound patent for imiquimod.
Does applying 3.75% imiquimod to individual lesions infringe the patent?
Not necessarily. Claim 1 requires application to the full face or balding scalp and the specified six-week schedule. Lesion-directed treatment may fall outside the literal scope, depending on the complete instructions and facts.
Can a generic avoid the patent by changing the cream base?
A different cream base may avoid a separate formulation claim, but it does not necessarily avoid the method claims. If the generic label still instructs the patented concentration, site, frequency, and six-week course, method-of-use risk remains.
Does a two-week treatment break have to occur for claim 1 to apply?
Yes. The claim requires a two-week non-treatment period separating the two two-week treatment periods.
Is FDA approval enough to permit launch after a Paragraph IV challenge?
No. FDA approval, patent litigation, any statutory stay, court judgment, and settlement terms can each affect launch timing.
References
-
U.S. Food and Drug Administration. (2012). Zyclara (imiquimod) cream, 3.75% prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
United States Patent and Trademark Office. (2012). U.S. Patent No. 8,236,816: Treatment of actinic keratosis with imiquimod. USPTO.
-
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
-
U.S. Food and Drug Administration. (2024). Generic drug user fee amendments and ANDA patent certification guidance. FDA.
